These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25542327)

  • 1. PALB2 and the risks for cancer: implications for clinical care.
    Smith EC
    Oncol Nurs Forum; 2015 Jan; 42(1):100-2. PubMed ID: 25542327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PALB2 analysis in BRCA2-like families.
    Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
    Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline PALB2 mutation analysis in breast-pancreas cancer families.
    Stadler ZK; Salo-Mullen E; Sabbaghian N; Simon JA; Zhang L; Olson SH; Kurtz R; Offit K; Foulkes WD; Robson ME; Tischkowitz M
    J Med Genet; 2011 Aug; 48(8):523-5. PubMed ID: 21415078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.
    Hellebrand H; Sutter C; Honisch E; Gross E; Wappenschmidt B; Schem C; Deissler H; Ditsch N; Gress V; Kiechle M; Bartram CR; Schmutzler RK; Niederacher D; Arnold N; Meindl A
    Hum Mutat; 2011 Jun; 32(6):E2176-88. PubMed ID: 21618343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
    García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
    Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry.
    Snyder C; Metcalfe K; Sopik V; Royer R; Zhang S; Narod SA; Akbari MR; Lynch HT
    Breast Cancer Res Treat; 2015 Apr; 150(3):637-41. PubMed ID: 25794774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer.
    Fernandes PH; Saam J; Peterson J; Hughes E; Kaldate R; Cummings S; Theisen A; Chen S; Trost J; Roa BB
    Cancer; 2014 Apr; 120(7):963-7. PubMed ID: 24415441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.
    Cybulski C; Kluźniak W; Huzarski T; Wokołorczyk D; Kashyap A; Jakubowska A; Szwiec M; Byrski T; Dębniak T; Górski B; Sopik V; Akbari MR; Sun P; Gronwald J; Narod SA; Lubiński J;
    Lancet Oncol; 2015 Jun; 16(6):638-44. PubMed ID: 25959805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.
    Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Apr; 114(3):457-62. PubMed ID: 18446436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
    Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
    Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recurrent mutation in PALB2 in Finnish cancer families.
    Erkko H; Xia B; Nikkilä J; Schleutker J; Syrjäkoski K; Mannermaa A; Kallioniemi A; Pylkäs K; Karppinen SM; Rapakko K; Miron A; Sheng Q; Li G; Mattila H; Bell DW; Haber DA; Grip M; Reiman M; Jukkola-Vuorinen A; Mustonen A; Kere J; Aaltonen LA; Kosma VM; Kataja V; Soini Y; Drapkin RI; Livingston DM; Winqvist R
    Nature; 2007 Mar; 446(7133):316-9. PubMed ID: 17287723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer.
    Blanco A; de la Hoya M; Balmaña J; Ramón y Cajal T; Teulé A; Miramar MD; Esteban E; Infante M; Benítez J; Torres A; Tejada MI; Brunet J; Graña B; Balbín M; Pérez-Segura P; Osorio A; Velasco EA; Chirivella I; Calvo MT; Feliubadaló L; Lasa A; Díez O; Carracedo A; Caldés T; Vega A
    Breast Cancer Res Treat; 2012 Feb; 132(1):307-15. PubMed ID: 22052327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.
    Kim JH; Choi DH; Cho DY; Ahn SH; Son BH; Haffty BG
    Breast Cancer Res Treat; 2010 Jul; 122(1):303-6. PubMed ID: 20213081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetrance analysis of the PALB2 c.1592delT founder mutation.
    Erkko H; Dowty JG; Nikkilä J; Syrjäkoski K; Mannermaa A; Pylkäs K; Southey MC; Holli K; Kallioniemi A; Jukkola-Vuorinen A; Kataja V; Kosma VM; Xia B; Livingston DM; Winqvist R; Hopper JL
    Clin Cancer Res; 2008 Jul; 14(14):4667-71. PubMed ID: 18628482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated.
    Harinck F; Kluijt I; van Mil SE; Waisfisz Q; van Os TA; Aalfs CM; Wagner A; Olderode-Berends M; Sijmons RH; Kuipers EJ; Poley JW; Fockens P; Bruno MJ
    Eur J Hum Genet; 2012 May; 20(5):577-9. PubMed ID: 22166947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort.
    McInerney NM; Miller N; Rowan A; Colleran G; Barclay E; Curran C; Kerin MJ; Tomlinson IP; Sawyer E
    Breast Cancer Res Treat; 2010 May; 121(1):203-10. PubMed ID: 19763819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
    Wark L; Novak D; Sabbaghian N; Amrein L; Jangamreddy JR; Cheang M; Pouchet C; Aloyz R; Foulkes WD; Mai S; Tischkowitz M
    Genes Chromosomes Cancer; 2013 May; 52(5):480-94. PubMed ID: 23341105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.